Pharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients' and physicians' preferences for testing and service delivery

Abstract

Aim Pharmacogenetic studies have identified the presence of the HLA‐A*31:01 allele as a predictor of cutaneous adverse drugs reactions (ADRs) to carbamazepine. This study aimed to ascertain the preferences of patients and clinicians to inform carbamazepine pharmacogenetic testing services. Methods Attributes of importance to people with epilepsy and neurologists were identified through interviews and from published sources. Discrete choice experiments (DCEs) were conducted in 82 people with epilepsy and 83 neurologists. Random‐effects logit regression models were used to determine the importance of the attributes and direction of effect. Results In the patient DCE, all attributes (seizure remission, reduction in seizure frequency, memory problems, skin rash and rare, severe ADRs) were significant. The estimated utility of testing was greater, at 0.52 (95% CI 0.19, 1.00) than not testing at 0.33 (95% CI –0.07, 0.81). In the physician DCE, cost, inclusion in the British National Formulary, coverage, negative predictive value (NPV) and positive predictive value (PPV) were significant. Marginal rates of substitution indicated that neurologists were willing to pay £5.87 for a 1 percentage point increase in NPV and £3.99 for a 1 percentage point increase in PPV. Conclusion The inclusion of both patients' and clinicians' perspectives represents an important contribution to the understanding of preferences towards pharmacogenetic testing prior to initiating carbamazepine. Both groups identified different attributes but had generally consistent preferences. Patients' acceptance of a decrease in treatment benefit for a reduced chance of severe ADRs adds support for the implementation of HLA‐A*31:01 testing in routine practice.

Developing patient-centred, feasible alternative care for adult emergency department users with epilepsy: protocol for the mixed-methods observational ‘Collaborate’ project

“…Aim is to capture a comprehensive range of perspectives, and sample size will be determined by data saturation. We anticipate72 76 recruiting a purposive sample of ~30 PWE, with or without an informal carer. Table 1 lists the inclusion and exclusion criteria.…”

CARer-ADministration of as-needed subcutaneous medication for breakthrough symptoms in homebased dying patients (CARiAD): study protocol for a UK-based open randomised pilot trial

“…The ordinal ranking across each group will be determined, and those ranked highest will be taken forward for DCE development. We have successfully implemented this method in previous DCEs, [53] and it is consistent with the reductiveness approach of attribute development. [52] We will also pilot the Carer Experience Scale as a means to estimate carer utility.…”

Assessing Feasibility of Delivering Pharmacogenetic Testing in a Community Pharmacy Setting

“…For many patients, this may represent their first experience receiving a clinical test in a pharmacy setting. Many patients may be more will ing to be tested since there is no cost, but studies have indicated patients' willingness to pay for genetic tests, particularly for older patients, with higher income and perceived clinical and personal utility [56][57][58][59]. A supplemental study to the proposed survey, such as a focus group study, may be of value to gather additional feedback from patients.…”